David Baker-Philadelphia

Interim CEO Company NameAlcobra Dates EmployedJun 2017 – Present Employment Duration8 mos LocationGreater Philadelphia Area Alcobra Ltd. (NASDAQ: ADHD) Chief Commercial Officer Company NameAlcobra Ltd. (NASDAQ: ADHD) Dates EmployedJan 2014 – Present Employment Duration4 yrs 1 mo LocationGreater Philadelphia Area Alcobra Ltd., founded in 2008 and headquartered in Tel Aviv, Israel, is an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including ADHD and Fragile X Syndrome. ADAIR (Abuse Deterrent Amphetamine Immediate Release) is the company’s lead investigational product candidate. Alcobra trades under the symbol “ADHD” on the NASDAQ Global Market and the company completed its initial public offering in May 2013. In addition to its headquarters in Tel Aviv, Alcobra has a U.S. office located outside of Philadelphia in Conshohocken, Pennsylvania. In my role as Chief Commercial Officer, I am responsible for leading all pre-launch commercial analysis and preparation for MDX, as well as leading business development efforts and supporting investor relations.